WPW
BMRN icon

Waldron Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waldron Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,106
Closed -$594K – 386
2023
Q1 		$594K Sell
6,106
-43
-0.7% -$4.46K 0.03% 227
2022
Q4 		$521K Hold
6,149
– – 0.03% 230
2022
Q3 		$521K Buy
6,149
+46
+0.8% +$4.1K 0.03% 230
2022
Q2 		$505K Buy
6,103
+100
+2% +$7.96K 0.03% 246
2022
Q1 		$462K Buy
6,003
+25
+0.4% +$2.09K 0.02% 261
2021
Q4 		$528K Buy
+5,978
New +$493K 0.03% 247

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Waldron Private Wealth's BMRN Position: Q2 2023 in Review

Waldron Private Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 6,106 shares — an estimated $594K sold.

Waldron Private Wealth first reported a position in BMRN in Q4 2021 and held it in 6 quarters. The position peaked at $594K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Waldron Private Wealth reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Waldron Private Wealth sold 6,106 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $594K.
  • Waldron Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Waldron Private Wealth's BioMarin Pharmaceuticals position peaked at $594K in Q1 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Waldron Private Wealth's 13F filing for Q2 2023, filed 7 Aug 2023.